Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The systemic vasculitides are multi-system disorders with significant mortality and morbidity and frequent relapses. Treatment is usually effective but fraught with potentially serious effects. Disease Assessment is important to ensure that patients receive the appropriate treatment. Disease Assessment should comprise measurement of disease activity, chronic irreversible damage and impairment of function. Serological markers can be helpful in assessing disease activity but lack sufficient sensitivity and specificity to be used on their own. Radiological techniques such as Magnetic Resonance Imaging, Ultrasound and Positron Emission Tomography show promise in the large vessel vasculitides but require validation in large studies. Clinical Assessment tools are the current gold standard for the assessment of disease activity, damage and function.

Type

Journal article

Journal

Clin exp rheumatol

Publication Date

03/2006

Volume

24

Pages

S92 - S99

Keywords

Antibodies, Antineutrophil Cytoplasmic, Biomarkers, Biopsy, Clinical Trials as Topic, Humans, Magnetic Resonance Imaging, Necrosis, Positron-Emission Tomography, Prognosis, Radiography, Sensitivity and Specificity, Severity of Illness Index, Ultrasonics, Vasculitis